|
Patient
|
Sex
|
Age (years)
|
Duration (years)a
|
Eyeb
|
Mouthc
|
Arthritisd
|
Lunge
|
Neurof
|
Parotidg
|
UWSFh
|
Schirmeri
|
OSSj
|
Chisholmk
|
ANA
|
Anti-SSAl
|
Anti-SSBl
|
RF (n < 0.2)
|
ACPA (n < 20)
|
IgG (mg/l)
|
Clinicalm
|
|---|
|
Detailed characteristics of the eight patients fulfilling only ACR criteria
|
|
1
|
F
|
25
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0.35
|
8
|
3
|
1
|
160
|
146
|
46
|
0.14
|
9
|
9.2
|
SS
|
|
2
|
F
|
63
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0.4
|
30
|
3
|
4
|
1,280
|
0
|
0
|
0
|
0
|
5.8
|
SS
|
|
3
|
F
|
34
|
1
|
1
|
0
|
1
|
0
|
0
|
0
|
0.2
|
20
|
4
|
4
|
1,280
|
174
|
0
|
0.5
|
250
|
16.2
|
RA
|
|
4
|
F
|
59
|
5
|
0
|
1
|
0
|
0
|
0
|
1
|
0.4
|
10
|
1
|
3
|
640
|
140
|
80
|
0.9
|
7
|
13.4
|
SS
|
|
5
|
F
|
61
|
5
|
1
|
1
|
0
|
0
|
0
|
0
|
0.5
|
8
|
3
|
3
|
0
|
0
|
0
|
0
|
0
|
12.1
|
Sicca
|
|
6
|
F
|
47
|
4
|
1
|
1
|
0
|
0
|
0
|
0
|
0.2
|
30
|
3
|
3
|
1,280
|
0
|
0
|
0
|
0
|
16.5
|
UCTD
|
|
7
|
F
|
57
|
1
|
1
|
1
|
1
|
0
|
1
|
0
|
0.5
|
30
|
4
|
4
|
160
|
0
|
0
|
0.52
|
250
|
12.7
|
RA
|
|
8
|
F
|
27
|
6
|
0
|
1
|
0
|
1
|
0
|
0
|
0.25
|
30
|
0
|
3
|
1,280
|
100
|
0
|
0.81
|
15
|
18.9
|
SLE
|
|
Detailed characteristics of the 15 patients fulfilling only AECG criteria
|
|
1
|
F
|
67
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0.005
|
5
|
2
|
3
|
160
|
0
|
0
|
0
|
0
|
11.7
|
SS
|
|
2
|
F
|
45
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0.001
|
5
|
2
|
2
|
640
|
154
|
0
|
0.05
|
0
|
13
|
SS
|
|
3
|
F
|
75
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0.2
|
0
|
2
|
3
|
0
|
0
|
0
|
0.34
|
0
|
9.3
|
SS
|
|
4
|
F
|
56
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0.005
|
25
|
2
|
2
|
1,280
|
24
|
152
|
0
|
0
|
9.9
|
SS
|
|
5
|
F
|
50
|
13
|
1
|
1
|
0
|
0
|
1
|
1
|
0.1
|
20
|
0
|
4
|
160
|
0
|
0
|
0
|
0
|
9.1
|
SS
|
|
6
|
F
|
69
|
6
|
1
|
1
|
0
|
0
|
0
|
0
|
0.25
|
5
|
1
|
4
|
1,280
|
0
|
0
|
0
|
0
|
10.3
|
SS
|
|
7
|
F
|
66
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0.486
|
5
|
2
|
3
|
320
|
0
|
0
|
0
|
0
|
7
|
SS
|
|
8
|
F
|
55
|
7
|
1
|
1
|
0
|
1
|
0
|
0
|
0.02
|
15
|
2
|
4
|
160
|
0
|
0
|
0
|
0
|
7.1
|
SS
|
|
9
|
F
|
43
|
3
|
1
|
1
|
0
|
0
|
0
|
0
|
0.15
|
5
|
1
|
1
|
640
|
85
|
0
|
0
|
0
|
12.6
|
SS
|
|
10
|
F
|
78
|
10
|
1
|
1
|
0
|
0
|
0
|
0
|
0.05
|
7
|
2
|
3
|
160
|
0
|
0
|
0
|
0
|
9.7
|
SS
|
|
11
|
M
|
64
|
2
|
1
|
1
|
0
|
1
|
0
|
0
|
0.2
|
0
|
0
|
4
|
320
|
0
|
0
|
0
|
28
|
22.6
|
SS
|
|
12
|
F
|
60
|
8
|
1
|
1
|
0
|
0
|
1
|
1
|
0.05
|
5
|
2
|
3
|
640
|
9
|
32
|
0
|
72
|
8.43
|
SS
|
|
13
|
F
|
58
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0.04
|
4
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
8.33
|
SS
|
|
14
|
F
|
43
|
10
|
0
|
1
|
0
|
0
|
0
|
0
|
0.06
|
0
|
1
|
2
|
320
|
40
|
0
|
0
|
0
|
10
|
SS
|
|
15
|
F
|
50
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0.05
|
15
|
1
|
3
|
0
|
0
|
0
|
0
|
0
|
9.7
|
SS
|
- ACPA, anti-citrullinated peptide antibodies; ACR, American College of Rheumatology; AECG, American–European Consensus Group; ANA, antinuclear antibody; F, female; IgG, serum level of immunoglobulin G; M, male; OSS, ocular staining score; SS, Sjögren’s syndrome. RA, rheumatoid arthritis; RF, rheumatoid factor; sicca, idiopathic sicca syndrome; SLE, systemic lupus erythematosus; UCTD, undifferentiated connective tissue disease; UWSF, unstimulated whole salivary flow. aDuration of the symptoms. bXerophthalmia (0, absent; 1, present). cXerostomia (0, absent; 1, present). dPresence of swollen and tender joints on the day of examination. eIncludes the presence of chronic dry cough or computed tomography-proven interstitial lung disease. fPatient with objective peripheral neuropathy. gPresence or history of parotidomegaly. hAbnormal if ≤0.1 ml/minute. iSchirmer’s test abnormal if ≤ 5 mm/5 minutes. jAbnormal if ≥ 3. kChisholm’s grading of the lymphocytic infiltration on minor salivary gland biopsy (grades 3 and 4 correspond to a focus score ≥1 focus of more than 50 lymphocytes/4 mm2). lAnti-SSA and anti-SSB antibodies (n < 40). mDiagnosis made by the physician, without reference to specific classification criteria.
